Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Recruiting Phase 3 Interventional Accepts healthy volunteers

Epidemiology and Biomarker Study in Alzheimer's Disease

NCT07142954
Conditions
Alzheimer Disease
Interventions
P-tau217 Test
Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 75 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2033
U.S. locations
1
States / cities
Houston, Texas
Conditions
Subjective Cognitive Impairment
Interventions
P-tau217, Standard of Care
Diagnostic Test · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
Interventions
Not listed
Lead sponsor
Neurogen Biomarking LLC
Industry
Eligibility
40 Years to 90 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Dearborn, Michigan • Flint, Michigan + 2 more
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Dementia (AD), Subjective Cognitive Decline (SCD), Cognitive Aging
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers

NCT05457998
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
Diagnostic Test
Lead sponsor
Butler Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Terminated Not applicable Interventional Accepts healthy volunteers

Home Test for Measuring Plasma P-tau217 in Alzheimer's Disease

NCT06622135
Conditions
Alzheimer Disease, Healthy Subjects
Interventions
Tasso Lancet Device
Device
Lead sponsor
Insight Research Institute
Other
Eligibility
55 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Chicago, Illinois • Flint, Michigan
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
Interventions
PrecivityAD2(TM) blood test
Other
Lead sponsor
C2N Diagnostics
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Timeline
2023 – 2025
U.S. locations
9
States / cities
San Francisco, California • Santa Monica, California • Park Ridge, Illinois + 6 more